페그인터페론 치료를 받는 만성바이러스성 간염 환자의 불안에 관한 연구
A Study on the Anxiety of the Chronic Viral Hepatitis Patients Receiving Pegylated Interferon Therapy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives The aim of this study was to clarify anxiety symptoms associated with the pegylated interferon (PEG-IFN) treatment and to determine which factors are associated with these anxiety symptoms. Methods The subjects were 30 patients with hepatitis B and C viral infections who were waiting to receive PEG-IFN treatment. For assessment of depressive and anxiety symptoms, the Beck Depression Inventory and the State-Trait Anxiety Inventory were used. Patients were examined before treatment and then prospectively during the 2 weeks, 4 weeks and 1 years of therapy. We analyzed the changes in anxiety and depression symptoms, and applied multiple regression analysis to identify factors that significantly affect the anxiety symptoms. Results Compared to pre-treatment baseline, anxiety symptoms increased 2 weeks after treatment, and gradually decreased 4 weeks, and 1 year after treatment. And, we analyzed the sub-factors of depressive symptoms that affect the anxiety symptoms. After 2 weeks of treatment, cognitive-affective factors and hypochondriasis factors of depressive symptoms had an effect on anxiety symptoms. Furthermore after 4 weeks of treatment, the cognitive-affective factors had an effect on anxiety symptoms. Conclusion In this study, we found a significant increase in anxiety symptoms after PEG-IFN treatment, and cognitive-affective depressive factors significantly affect anxiety symptoms.
Abstract
Objectives The aim of this study was to clarify anxiety symptoms associated with the pegylated interferon (PEG-IFN) treatment and to determine which factors are associated with these anxiety symptoms. Methods The subjects were 30 patients with hepatitis B and C viral infections who were waiting to receive PEG-IFN treatment. For assessment of depressive and anxiety symptoms, the Beck Depression Inventory and the State-Trait Anxiety Inventory were used. Patients were examined before treatment and then prospectively during the 2 weeks, 4 weeks and 1 years of therapy. We analyzed the changes in anxiety and depression symptoms, and applied multiple regression analysis to identify factors that significantly affect the anxiety symptoms. Results Compared to pre-treatment baseline, anxiety symptoms increased 2 weeks after treatment, and gradually decreased 4 weeks, and 1 year after treatment. And, we analyzed the sub-factors of depressive symptoms that affect the anxiety symptoms. After 2 weeks of treatment, cognitive-affective factors and hypochondriasis factors of depressive symptoms had an effect on anxiety symptoms. Furthermore after 4 weeks of treatment, the cognitive-affective factors had an effect on anxiety symptoms. Conclusion In this study, we found a significant increase in anxiety symptoms after PEG-IFN treatment, and cognitive-affective depressive factors significantly affect anxiety symptoms.
참고문헌 (48)
- Bissinger AL, "Epidemiology and genotyping of patients with chronic hepatitis B: genotype shifting observed in patients from central Europe", Pol J Microbiol, 64, pp.15~21 (2015)
- Croagh CM, "Genotypes and viral variants in chronic hepatitis B: a review of epidemiology and clinical relevance", World J Hepatol, 7, pp.289~303 (2015)
- Zdilar D, "Hepatitis C, interferon alfa, and depression", Hepatology, 31, pp.1207~1211 (2000)
- Renault PF, "Psychiatric complications of long-term interferon alfa therapy", Arch Intern Med, 147, pp.1577~1580 (1987)
- Dieperink E, "A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C", Psychosomatics, 44, pp.104~112 (2003)
- Reddy KR, "Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C", Hepatology, 33, pp.433~438 (2001)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Gohier B, "Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients", World J Biol Psychiatry, 4, pp.115~118 (2003)
- Navinés R, "Depressive and anxiety disorders in chronic hepatitis C patients: reliability and validity of the Patient Health Questionnaire.", J Affect Disord, 138, pp.343~351 (2012)
- Lotrich FE, "Depression following pegylated interferon-alpha: characteristics and vulnerability", J Psychosom Res, 63, pp.131~135 (2007)
- Martín-Santos R, "De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C", Aliment Pharmacol Ther, 27, pp.257~265 (2008)
- Kessler RC, "Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys", Am J Psychiatry, 156, pp.1915~1923 (1999)
- King PD, "Hepatitis C virus infection in non-Hodgkin’s lymphoma", Clin Lab Haematol, 20, pp.107~110 (1998)
- Middeldorp CM, "The co-morbidity of anxiety and depression in the perspective of genetic epidemiology. A review of twin and family studies", Psychol Med, 35, pp.611~624 (2005)
- Demirkan A, "Genetic risk profiles for depression and anxiety in adult and elderly cohorts", Mol Psychiatry, 16, pp.773~783 (2011)
- Anisman H, "Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder", J Psychiatry Neurosci, 34, pp.4~20 (2009)
- Bayat N, "Symptoms of anxiety and depression: a comparison among patients with different chronic conditions", J Res Med Sci, 16, pp.1441~1447 (2011)
- Katon W, "The association of depression and anxiety with medical symptom burden in patients with chronic medical illness", Gen Hosp Psychiatry, 29, pp.147~155 (2007)
- McLaughlin TP, "Overlap of anxiety and depression in a managed care population: prevalence and association with resource utilization", J Clin Psychiatry, 67, pp.1187~1193 (2006)
- Marciniak MD, "The cost of treating anxiety: the medical and demographic correlates that impact total medical costs", Depress Anxiety, 21, pp.178~184 (2005)
- Sareen J, "Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions", Arch Intern Med, 166, pp.2109~2116 (2006)
- Stein MB, "Functional impact and health utility of anxiety disorders in primary care outpatients", Med Care, 43, pp.1164~1170 (2005)
- Spielberger CD, "Manual for the State-trait anxiety inventory (form Y) (“self-evaluation questionnaire”)" (1983), Consulting Psychologists Press
- Kim JT, "Relationship between trait anxiety and sociality", pp.1978
- Beck AT, "An inventory for measuring depression", Arch Gen Psychiatry, 4, pp.561~571 (1961)
- Lee MK, "A Standardization study of Beck Depression Inventory 1-Korean version (K-BDI)", Korean J Psychopathol, 4, pp.77~95 (1995)
- Yang HJ, "Factor analysis of the beck depression inventory in anxiety disorder", pp.2011
- Bonaccorso S, "Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms", Psychiatry Res, 105, pp.45~55 (2001)
- Mahajan S, "Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection", J Psychosom Res, 77, pp.109~115 (2014)
- Boscarino JA, "Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS)", Hepatology, 61, pp.802~811 (2015)
- Loftis JM, "Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study", J Psychosom Res, 74, pp.57~63 (2013)
- Ning K, "On preprocessing and antisymmetry in de novo peptide sequencing: improving efficiency and accuracy", J Bioinform Comput Biol, 6, pp.467~492 (2008)
- O’Donovan A, "Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships", Brain Behav Immun, 24, pp.1074~1077 (2010)
- Udina M, "Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms", Psychoneuroendocrinology, 38, pp.1830~1831 (2013)
- Dantzer R., "Cytokine-induced sickness behavior: where do we stand?", Brain Behav Immun, 15, pp.7~24 (2001)
- Sakić B, "Reduced preference for sucrose in autoimmune mice: a possible role of interleukin-6", Brain Res Bull, 44, pp.155~165 (1997)
- Späth-Schwalbe E, "Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men", J Clin Endocrinol Metab, 83, pp.1573~1579 (1998)
- Connor TJ, "An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat", Neuroscience, 84, pp.923~933 (1998)
- Licinio J, "Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes", Semin Oncol, 25(1 Suppl 1), pp.30~38 (1998)
- Kim H, "Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression", J Clin Invest, 122, pp.2940~2954 (2012)
- Morikawa O, "Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter", Eur J Pharmacol, 349, pp.317~324 (1998)
- Kamata M, "Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain", Eur Neuropsychopharmacol, 10, pp.129~132 (2000)
- Raison CL, "CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression", Mol Psychiatry, 15, pp.393~403 (2010)
- Pergamin-Hight L, "Variations in the promoter region of the serotonin transporter gene and biased attention for emotional information: a metaanalysis.", Biol Psychiatry, 71, pp.373~379 (2012)
- De La Garza R 2nd, "Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats", Prog Neuropsychopharmacol Biol Psychiatry, 29, pp.781~792 (2005)
- Udina M, "Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis", J Clin Psychiatry, 73, pp.1128~1138 (2012)
- Carrión JA, "A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C", J Hepatol, 59, pp.926~933 (2013)
- Neri S, "A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin", J Clin Gastroenterol, 44, pp.e210~e217 (2010)